Allergy is the most common chronic disease in Europe – more than 150 million Europeans suffer from chronic allergic diseases and the current prediction is that by 2025 half of the entire EU population will be affected. Up to 20% of patients with allergies live with a severe debilitating form of their condition, struggling with the fear of a possible asthma attack, anaphylactic shock, or even death from an allergic reaction.
The aim of the project is to develop a POC analytical platform for a more precise and predictive personalized diagnosis of allergies, supporting personalized diagnostics and treatment monitoring. Aiming at hazelnut and peanut allergies, we are tackling two of the most threatening and frequent food allergens. The study will develop a less invasive and burdening diagnosis tool for allergy, allowing early recognition and improving quality of care for patients.